Issue link: https://www.e-digitaleditions.com/i/977310
4 May 2018 Tablets & Capsules research "Body on a chip" could help predict side effects during drug development CAMBRIDGE, MA—MIT engin- eers have created a "body on a chip," a microfluidic platform that can be used to evaluate new drug products and predict possible complex adverse drug reactions before human testing. Researchers were able to put as many as 10 organ tissues in clusters of 1 to 2 million cells in separate compartments in the platform and regulate the flow of substances between them in real time, which accurately replicates human organ interactions for weeks at a time. This allows researchers to measure the effects of drug products on different parts of the body and could reveal whether a drug intended to treat one organ will have adverse effects on another. markets Pharmaceutical excipients market to surpass $8 billion by 2023 NORTHBROOK, IL—The global pharmaceutical excipients market is forecast to grow at a compound annual rate of 5.9 percent through 2023, reaching $8.53 billion, according to a report by MarketsandMarkets. Factors driving market growth include advancements in functional excipients, a growing generics market thanks to patent expirations, the emergence of multifunctional and co-processed excipients, and the pharmaceutical manufacturing industry's focus on emerging markets. The report identifies Ashland, BASF, Dow-DuPont, Roquette, Evonik, Kerry, Croda, Associated British Foods, Archer Daniels Midland, Lubrizol, Wacker Chemie, Innophos, and Signet as major players in this market. industry news Avara acquires GSK South Carolina manufacturing facility NORWALK, CT—Avara Pharm- aceutical Services, a CDMO, has acquired the GlaxoSmithKline (GSK) consumer healthcare manufacturing facility in Aiken, SC. The acquisition adds to Avara's solid dosage manu- facturing capabilities in the US. Bosch to offer data mining for solid dosage manufacturing FRANKFURT, Germany—Bosch Packaging Technology has announced that it will add data mining to its solid dosage manufacturing services. The goal of this service is to evaluate existing machine data collected by sensors to identify and eliminate root causes of failures in the production cycle. The service will be offered by the company's process technology subsidiary Hüttlin, Schopfheim, Germany. Probi to develop probiotic strains with Cilag REDMOND, WA—Probi, a bio- engineering company, has signed a long- term development agreement with Cilag, a Johnson & Johnson Family pharma-